Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib-Reference-Cited by-同舟云学术

Keratoacanthomas and Squamous Cell Carcinomas in Patients Receiving Sorafenib

Published:2009-08-10 Issue:23 Volume:27 Page:e59-e61
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Arnault Jean Philippe¹,Wechsler Janine²,Escudier Bernard³,Spatz Alain⁴,Tomasic Gorana⁴,Sibaud Vincent⁵,Aractingi Selim⁶,Grange Jean-Didier⁷,Poirier-Colame Vichnou¹,Malka David³,Soria Jean-Charles³,Mateus Christine¹,Robert Caroline¹

Affiliation:

1. Dermatology Service, Gustave Roussy Institute, France

2. Pathology Department, Henri-Mondor University Hospital, Créteil, France

3. Department of Medicine, Gustave Roussy Institute, Villejuif, France

4. Pathology Department, Gustave Roussy Institute, Villejuif, France

5. Dermatology Department, Institut Claudius Regaud, Toulouse, France

6. Dermatology Service, Tenon Hospital, Paris, France

7. Gastrointestinal Service, Tenon Hospital, Paris, France

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2009.23.4823

Reference20 articles.

1. Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor

2. Dermatologic symptoms associated with the multikinase inhibitor sorafenib

3. Cutaneous side-effects of kinase inhibitors and blocking antibodies

4. Multiple Squamous Cell Carcinomas of the Skin After Therapy With Sorafenib Combined With Tipifarnib

5. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor

Cited by 145 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study;Clinical and Translational Science;2024-06

2. Skin Malignancies Due to Anti-Cancer Therapies;Cancers;2024-05-22

3. An effective two-stage NMBzA-induced rat esophageal tumor model revealing that the FAT-Hippo-YAP1 axis drives the progression of ESCC;Cancer Letters;2024-04

4. Progress in the study of ferroptosis in cancer treatment: State-of-the-Art;Chemico-Biological Interactions;2023-02

5. Multiple keratoacanthomas induced by treatment with dasatinib and bosutinib for chronic myeloid leukemia: A case report and literature review;The Journal of Dermatology;2022-12-30